STAT Plus: A sadly familiar disappointment in Alzheimer’s research
After years of failed attempts to treat Alzheimer’s disease by targeting a toxic brain plaque called amlyoid, a critical mass of scientists turned their attention to a seemingly more promising target: a tangled cranial protein called tau. But the failure of a closely watched tau treatment suggests history may repeat itself for neurology’s next-best idea.
On Wednesday, the Swiss drug maker AC Immune said its anti-tau antibody missed its primary and secondary goals in a placebo-controlled study that enrolled more than 450 people with early-stage Alzheimer’s.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: A sadly familiar disappointment in Alzheimer’s research »
